Navigation Links
Drug-resistant melanoma tumors shrink when therapy is interrupted
Date:1/9/2013

Researchers in California and Switzerland have discovered that melanomas that develop resistance to the anti-cancer drug vemurafenib (marketed as Zelboraf), also develop addiction to the drug, an observation that may have important implications for the lives of patients with late-stage disease.

The team, based at the University of California, San Francisco (UCSF), the Novartis Institutes for Biomedical Research (NIBR) in Emeryville, Calif., and University Hospital Zurich, found that one mechanism by which melanoma cells become resistant to vemurafenib also renders them "addicted" to the drug. As a result, the melanoma cells nefariously use vemurafenib to spur the growth of rapidly progressing, deadly and drug-resistant tumors.

As described this week in the journal Nature, the team built upon this basic discovery and showed that adjusting the dosing of the drug and introducing an on-again, off-again treatment schedule prolonged the life of mice with melanoma.

"Remarkably, intermittent dosing with vemurafenib prolonged the lives of mice with drug-resistant melanoma tumors," said co-lead researcher Martin McMahon, PhD, the Efim Guzik Distinguished Professor of Cancer Biology in the UCSF Helen Diller Family Comprehensive Cancer Center.

It is therefore possible that a similar approach may extend the effectiveness of the drug for people an idea that awaits testing in clinical trials.

Investigated through a public-private partnership, the research was spearheaded by the study's first author Meghna Das Thakur, PhD, a Novartis Presidential Postdoctoral Fellow, who was co-mentored by McMahon at UCSF and Darrin Stuart, PhD at NIBR.

McMahon is supported by the Melanoma Research Alliance, the National Cancer Institute and the UCSF Helen Diller Family Comprehensive Cancer Center, which is one of the country's leading research and clinical care centers, and is the only comprehensive cancer center in the San Fra
'/>"/>

Contact: Jason Socrates Bardi
jason.bardi@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Moffitt researcher investigates 2-drug synergy to treat drug-resistant chronic myeloid leukemia
2. Discovery of essential genes for drug-resistant bacteria reveals new, high-value drug targets
3. Molecule shows effectiveness against drug-resistant myeloma
4. Alarming Rise Seen in Drug-Resistant Tuberculosis
5. African Chimps Carry Drug-Resistant, Human-Linked Staph
6. Computational analysis identifies drugs to treat drug-resistant breast cancer
7. Scientists develop new strategy to overcome drug-resistant childhood cancer
8. Rare Drug-Resistant Bacteria Spotted in U.S. Hospital
9. New Medicine Might Fight Drug-Resistant TB, Study Says
10. Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains
11. Kinase test may yield big gains for drug-resistant cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug-resistant melanoma tumors shrink when therapy is interrupted
(Date:9/22/2014)... PA (PRWEB) September 22, 2014 The ... in the Greater Philadelphia region each year, is considered ... year, CNC manufacturer MK Precision is proud to announce ... accomplished group. MK Precision will attend the Philadelphia ... one of the premiere business events of the year, ...
(Date:9/22/2014)... study pulls back the curtain on one of the ... and income between physicians who perform operations, procedures or ... perception, the research indicates, the physician payment system is ... doctors. , The new findings counter the widely held ... explains why doctors who perform procedures often earn nearly ...
(Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. 22, 2014 ... aware of online physician-rating sites, and more than one-quarter have ... to a new national study. The findings -- based ... that negative online ratings may dissuade parents from choosing a ... neighbor. Conversely, a positive online rating may sway parents ...
(Date:9/22/2014)... Asians living in Canada have a higher rate of ... with while people, McMaster researchers have found. , ... Medical Association Journal (CMAJ Open) and may be ... fastest-growing ethnic groups in the country is the more ... comprising about three percent of the population. They include ...
(Date:9/22/2014)... 2014. Kessler researchers have published a pilot study ... program in people with multiple sclerosis (MS). ... perceived stress, and pain. "Development and effectiveness ... with MS: Description and outcomes" was epublished ahead ... International Journal of MS Care (doi: 10.7224/1537-2073.2013-045). ...
Breaking Medicine News(10 mins):Health News:MK Precision Announces Spot on Philadelphia 100 Fastest Growing Companies 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 2Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 3Health News:Higher risk of heart disease for South Asians in Canada 2
... Oct. 21 Today more than ever, employers,are looking ... call for stabilizing influences, and wellness is such an,influence," ... time to put workplace wellness and employee health on ... to begin to realize the financial and,other benefits of ...
... celebrates the contributions that pharmacy technicians make on the 18th ... ... Washington, D.C. (PRWEB) October 21, 2008 -- Today marks ... Pharmacy Technician Certification Board (PTCB) applauds the valuable contributions ...
... While a poverty-alleviation program launched by the Mexican government ... around the world has led to improved health and ... of California, Berkeley, researchers says that the cash component ... The program, called Oportunidades, provides money to impoverished families ...
... Announces It Reduced Debt by $6.1 Million in ... 21 LodgeNet,Interactive Corporation (Nasdaq: LNET ), ... hospitality and healthcare businesses, today,announced that it will ... Tuesday, October 28, 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20080115/AQTU120LOGO ...
... Inc. (OTC,Bulletin Board: VSPC) subsidiary Ionfinity has ... its proposal entitled "Miniature Electronic Sniffer,for Navy ... by the Navy,s,Small Business Technology Transfer (STTR) ... result in a field demonstration of high,sensitivity ...
... ProLindac Is Safe And Active in Recurrent Ovarian ... DALLAS, Oct. 21 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin ... recent results of the company,s proprietary polymer DACH,platinum ... being,presented this week at a major international oncology ...
Cached Medicine News:Health News:Even During Financial Crisis Investing in Wellness is Good Business 2Health News:National Pharmacy Technician Day Celebrated with Focus on Quality -- Pharmacy Technician Certification Board (PTCB) Touts Importance of Certified Technicians 2Health News:National Pharmacy Technician Day Celebrated with Focus on Quality -- Pharmacy Technician Certification Board (PTCB) Touts Importance of Certified Technicians 3Health News:Extra cash from government program linked to higher risk of adult obesity 2Health News:Extra cash from government program linked to higher risk of adult obesity 3Health News:LodgeNet Interactive to Report Third Quarter Results on October 28th 2Health News:VIASPACE Subsidiary Wins $786,000 U.S. Navy Contract 2Health News:Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008 2Health News:Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008 3
(Date:9/22/2014)... , Sept. 22, 2014 Avanir Pharmaceuticals, Inc. ... is offering to sell $200 million of its common ... Bank Securities and BofA Merrill Lynch are acting as ... the underwriters a 30-day option to purchase additional shares ... be sold in the offering are being sold by ...
(Date:9/22/2014)... NEW DELHI , September 22, 2014 ... announced on   September 25   The ... corner and we are excited to announce the final ... winners will be announced on the evening of September 25 at The ... nominations were picked from applicants based on a variety ...
(Date:9/22/2014)... , Sept. 22, 2014 Decision Resources Group ... market is expected to be worth $2 billion (U.S. dollars), ... over the next five years (to 2018). This growth comes ... 4.8 percent in 2013 and 4.9 percent expected over the ... pharmaceutical landscape is small but highly competitive. The pharmaceutical market ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3
... with Docetaxel in Advanced Breast Cancer - , , ... Advanced Lung Cancer - , , - 64% ... Cancer - , , - Data in All ... - , , - Positive Initial Data across ...
... Calif., June 2 This month,s Journal of Aerosol ... clinical trial results for PARI Pharma,s L-CsA, inhaled liposomal ... Drug Designation from the Food and Drug Administration for ... the prevention and treatment of bronchiolitis obliterans, a devastating, ...
Cached Medicine Technology:Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials 2Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials 3Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials 4Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials 5Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials 6PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans 2PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans 3PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans 4
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
9mm Gently Curved Jaws, WIth Lock, in Titanium....
5mm Gently Curved Wing Span, With Centering Pin, Low Profile; in stainless steel....
Retractable, straight double Lancet Blade, 15 Degree Angle , available in variations; Titanium handle...
Medicine Products: